+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Antihypertensives Market Report to 2031

22 February 2021

Visiongain has published a new report on Antihypertensives Market Report to 2031. According to the Visiongain analysis, the global antihypertensives market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global antihypertensives market is segmented by type (Diuretics, Beta-blockers, ACE inhibitors, Angiotensin II receptor blockers, calcium channel blockers, Others) By end user (Retail Pharmacy, Hospitals, Others) By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antihypertensives Companies. PLUS COVID-19 Recovery Scenarios.

Global Antihypertensives Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Surge in geriatric population and increasing prevalence of high blood pressure or hypertension globally are some of the factors driving the growth of the global antihypertensives market.

COVID-19 Impact on the Global Antihypertensives Market
The global pandemic (COVID-19) is caused due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which binds target epithelial lung cells through angiotensin‐converting enzyme 2 in humans. The patients with hypertension along with COVID‐19 are at higher risk. However, the patients without antihypertensive treatment are significantly at higher risk of mortality.

Market Driver
Change in lifestyle, increasing obese population
Controlling blood pressure is of significant health priority to reduce the serious health condition associated with hypertension, which includes strokes, heart failure, stroke, and end‐stage renal failures. Obesity is considered as the major factor to develop hypertension. The change in lifestyle such as inactivity, high calorie intake, leads to obesity. According to WHO, more than 1.9 billion people were overweight in 2016. About 41.0% of obese Americans have hypertension, however, the change in lifestyle is recommended for hypertension patients. The change in lifestyle & increasing incidences of obesity, enhance the demand for antihypertensives in the market.

Increasing prevalence of high blood pressure or hypertension globally.
The hypertension is associated with the risk strokes, heart disease, which are considered as the leading causes of mortality in the US. Hypertension as a primary or contributing cause in US, which nearly accounts half a million deaths. Hypertension is uncontrolled in about 50% of the more than one third of Americans older than 20 years. However, only about 1 in 4 adults (24%) with hypertension have under control condition.

Market Opportunity

High growth of hypertensives in developing economies
Hypertension is a serious medical condition, which significantly increases the risks of heart, kidney, and other diseases. As per WHO, it is estimated about 1.13 billion people have hypertension, out of which two-thirds of the population lives in low- and middle-income countries. The modifiable risk factors associated with hypertensives includes obesity, consumption of alcohol, physical inactivity, whereas the non- modifiable factors include ageing, family history of hypertension, co-existing diseases such as diabetes or kidney disease. Most of the increasing hypertensive cases are highly seen in low- and middle-income countries.

Competitive Landscape
Pfizer Inc., Novartis AG, Merck & Co., Inc, Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd, Johnson & Johnson, AstraZeneca PLC, AbbVie, Cipla Limited, Sun Pharmaceutical Industries Ltd., Sanofi are some of the key players contributing to the growth of the global antihypertensives market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.

For instance, June 2019, Mankind Pharma launched Zolahart (Azilsartan), antihypertensive drug at affordable price. The company introduce the drug & focuses to reduce commonly related disease of hypertension. Azilsartan, a new generation anti-hypertensive drug, which is safe to use in hypertensive patients with comorbid conditions such as diabetes or Chronic Kidney Disease.

In April 2019, Cipla Limited announced final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan drug from the United States Food and Drug Administration (US FDA). The drug is endothelin receptor antagonist indicated to treat pulmonary arterial hypertension.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Bioreactors Market Report 2023-2033

The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.

29 September 2023


Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033

The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.

27 September 2023


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033

The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.

25 September 2023


Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033

The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.

21 September 2023